Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenolsulfonic acid is an organic compound consisting of a benzene ring substituted with both a hydroxyl group and a sulfonic acid group. It is used primarily as an ingredient in topical agents for the treatment of ulcerating oral mucosal lesions such as recurrent aphthous stomatitis (canker sores). In pharmaceutical products like Debacterol, it acts as a chemical cautery agent that destroys cells at the application site—including nerve endings—providing pain relief and promoting healing. Phenolsulfonic acid also possesses antimicrobial properties and has been used in deodorants to inhibit microbial growth on the skin. Its mechanism of action in topical oral applications is local tissue destruction (chemical cauterization), not antiseptic or anesthetic activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Phenolsulfonic acid.